Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
Authors
Keywords
-
Journal
Cost Effectiveness and Resource Allocation
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-08-09
DOI
10.1186/s12962-023-00458-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
- (2023) Eileen M. Dunne et al. ARCHIVOS DE BRONCONEUMOLOGIA
- PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)
- (2022) Christian Theilacker et al. Microorganisms
- 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae
- (2022) Thomas Chandler et al. Microorganisms
- Cost-utility analysis of the universal pneumococcal vaccination programme for older adults in Norway
- (2022) Liv Solvår Nymark et al. Human Vaccines & Immunotherapeutics
- Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease
- (2022) Diana Mendes et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23
- (2022) Jens Olsen et al. JOURNAL OF MEDICAL ECONOMICS
- Effectiveness of Pneumococcal Vaccination Against Hospitalized Pneumococcal Pneumonia in Older Adults: A Prospective, Test-Negative Study
- (2021) Jung Yeon Heo et al. JOURNAL OF INFECTIOUS DISEASES
- The Risk of Invasive Pneumococcal Disease Differs between Risk Groups in Norway Following Widespread Use of the 13-Valent Pneumococcal Vaccine in Children
- (2021) Brita Askeland Winje et al. Microorganisms
- Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years
- (2021) Brandon Essink et al. CLINICAL INFECTIOUS DISEASES
- A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cps Fragment from an Oral Streptococcus
- (2020) Feroze Ganaie et al. mBio
- A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population
- (2020) Jacob Dag Berild et al. Pathogens
- Cost-effectiveness of pneumococcal vaccination for elderly in Sweden
- (2020) Ellen Wolff et al. VACCINE
- Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study
- (2020) Hannah Lawrence et al. PLOS MEDICINE
- Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study
- (2019) Jong Hun Kim et al. VACCINE
- Pneumococcal Disease and the Effectiveness of the PPV23 Vaccine in Adults: A Two-Stage Bayesian Meta-Analysis of Observational and RCT Reports
- (2018) Hamid Latifi-Navid et al. Scientific Reports
- Impact of the 13-valent pneumococcal conjugate vaccine on incidence of all-cause pneumonia in adults aged ≥ 60 years – a population-based retrospective cohort study
- (2018) Martin Kolditz et al. CLINICAL INFECTIOUS DISEASES
- Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies
- (2017) Myint Tin Tin Htar et al. PLoS One
- Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
- (2015) Marie-Josée J. Mangen et al. EUROPEAN RESPIRATORY JOURNAL
- Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
- (2015) Marc J.M. Bonten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pneumococcal infection in adults: burden of disease
- (2013) J.J.C. Drijkoningen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Serotype Distribution in Non-Bacteremic Pneumococcal Pneumonia: Association with Disease Severity and Implications for Pneumococcal Conjugate Vaccines
- (2013) Thomas Benfield et al. PLoS One
- Understanding the burden of pneumococcal disease in adults
- (2012) F. Blasi et al. CLINICAL MICROBIOLOGY AND INFECTION
- Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales
- (2012) Nick J. Andrews et al. VACCINE
- Using Health State Utility Values from the General Population to Approximate Baselines in Decision Analytic Models when Condition-Specific Data are Not Available
- (2011) Roberta Ara et al. VALUE IN HEALTH
- Clinical and economic burden of community-acquired pneumonia among adults in Europe
- (2010) T Welte et al. THORAX
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started